Have you seen our new ‘How I treat…’ features? Become a member (it’s free!) and discover the latest advice from fellow clinicians here >>>

NICE recommends Osimertinib (Tagrisso®) for EGFR+ Stage 1b–3A NSCLC within the Cancer Drugs Fund

Written by Louis Gautier, Future Science Group

NICE recently published final draft guidance recommending osimertinib (Tagrisso®), a 3rd generation EGFR-TKI, for use in early-stage EGFR T790M mutation-positive NSCLC patients who have progressed on previous EGFR-targeted therapies and who have had their tumor surgically resected. Surgical removal of tumors is the preferred treatment option for many patients with early-stage NSCLC because it has a relatively high potential for curing the disease. However, the cancer still reoccurs in about 45% of people who have this treatment and effective neoadjuvant and adjuvant treatments are under thorough investigation. There are currently no targeted adjuvant treatments available in England for NSCLC patients...

To view this content, please register now for access

It's completely free